Persistent organic pollutants promote aggressiveness in prostate cancer.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
09 2023
Historique:
received: 15 09 2022
accepted: 18 07 2023
revised: 10 07 2023
medline: 18 9 2023
pubmed: 17 8 2023
entrez: 16 8 2023
Statut: ppublish

Résumé

Increasing evidence points towards a causal link between exposure to persistent organic pollutants (POPs) with increased incidence and aggressivity of various cancers. Among these POPs, dioxin and PCB-153 are widely found in our environment and represent a significant source of contamination. Dioxin exposure has already been linked to cancer such as non-Hodgkin's lymphoma, but remains to be more extensively investigated in other cancers. Potential implications of dioxin and PCB-153 in prostate cancer progression spurred us to challenge both ex vivo and in vivo models with low doses of these POPs. We found that dioxin or PCB-153 exposure increased hallmarks of growth and metastasis of prostate cancer cells ex vivo and in grafted NOD-SCID mice. Exposure induced histopathological carcinoma-like patterns in the Pten

Identifiants

pubmed: 37587334
doi: 10.1038/s41388-023-02788-2
pii: 10.1038/s41388-023-02788-2
doi:

Substances chimiques

2,4,5,2',4',5'-hexachlorobiphenyl ZRU0C9E32O
Persistent Organic Pollutants 0
Dioxins 0
Polychlorinated Dibenzodioxins 0
Acetyltransferases EC 2.3.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2854-2867

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Références

International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. 2,3,7,8-tetrachlorodibenzo-para-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 3,3′,4,4′,5-pentachlorobiphenyl. In: Chemical agents and related occupations - IARC monographs on the evaluation of carcinogenic risks to humans, 100F. 2012.
International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Polychlorinated biphenyls and polybrominated biphenyls. IARC monographs on the evaluation of carcinogenic risks to humans, 107; 2016.
Hardell L, Andersson SO, Carlberg M, Bohr L, Van Bavel B, Lindström G, et al. Adipose tissue concentrations of persistent organic pollutants and the risk of prostate cancer. J Occup Environ Med. 2006;48:700–7.
pubmed: 16832227 doi: 10.1097/01.jom.0000205989.46603.43
Ali I, Julin B, Glynn A, Högberg J, Berglund M, Johansson JE, et al. Exposure to polychlorinated biphenyls and prostate cancer: Population-based prospective cohort and experimental studies. Carcinogenesis 2016;37:1144–51.
pubmed: 27742691
Xu J, Ye Y, Huang F, Chen H, Wu H, Huang J, et al. Association between dioxin and cancer incidence and mortality: a meta-analysis. Sci Rep. 2016;6:38012.
pubmed: 27897234 pmcid: 5126552 doi: 10.1038/srep38012
Emeville E, Giusti A, Coumoul X, Thomé JP, Blanchet P, Multigner L. Associations of plasma concentrations of dichlorodiphenyldichloroethylene and polychlorinated biphenyls with prostate cancer: a case–control study in Guadeloupe (French West Indies). Environ Health Perspect. 2015;123:317–23.
pubmed: 25493337 doi: 10.1289/ehp.1408407
Leng L, Chen X, Li CP, Luo XY, Tang NJ. 2,3,7,8-Tetrachlorodibezo-p-dioxin exposure and prostate cancer: A meta-analysis of cohort studies. Public Health. 2014;128:207–13.
pubmed: 24461260 doi: 10.1016/j.puhe.2013.10.006
Dragan YP, Schrenk D. Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion. Food Addit Contam. 2000;17:289–302.
pubmed: 10912243 doi: 10.1080/026520300283360
Moore RW, Fritz WA, Schneider AJ, Lin TM, Branam AM, Safe S, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice. Toxicol Appl Pharmacol. 2016;305:242–9.
pubmed: 27151233 pmcid: 4982706 doi: 10.1016/j.taap.2016.04.018
Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat Rev Cancer. 2014;14:801–14.
pubmed: 25568920 pmcid: 4401080 doi: 10.1038/nrc3846
Kollara A, Brown TJ. Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. J Steroid Biochem Mol Biol. 2010;118:51–58.
pubmed: 19815066 doi: 10.1016/j.jsbmb.2009.09.017
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
pubmed: 21376230 doi: 10.1016/j.cell.2011.02.013
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.
pubmed: 15516961 doi: 10.1038/nrc1478
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.
pubmed: 31819192 doi: 10.1038/s41416-019-0650-z
Lynen F, Ochoa S. Enzymes of fatty acid metabolism. BBA - Biochim Biophys Acta. 1953;1000:281–96.
Middleton B, Bartlett K, Romanos A, Vazquez JG, Conde C, Cannon RA, et al. 3-Ketothiolase deficiency. Eur J Pediatr. 1986;144:586–9.
pubmed: 3709573 doi: 10.1007/BF00496042
Haapalainen AM, Meriläinen G, Wierenga RK. The thiolase superfamily: condensing enzymes with diverse reaction specificities. Trends Biochem Sci. 2006;31:64–71.
pubmed: 16356722 doi: 10.1016/j.tibs.2005.11.011
Haapalainen AM, Meriläinen G, Pirilä PL, Kondo N, Fukao T, Wierenga RK. Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase: The importance of potassium and chloride ions for its structure and function. Biochemistry. 2007;46:4305–21.
pubmed: 17371050 doi: 10.1021/bi6026192
Fan J, Shan C, Kang HB, Elf S, Xie J, Tucker M, et al. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell. 2014;53:534–48.
pubmed: 24486017 pmcid: 3943932 doi: 10.1016/j.molcel.2013.12.026
Fan J, Lin R, Xia S, Chen D, Elf SE, Liu S, et al. Tetrameric acetyl-CoA acetyltransferase 1 is important for tumor growth. Mol Cell. 2016;64:859–74.
pubmed: 27867011 pmcid: 5135630 doi: 10.1016/j.molcel.2016.10.014
Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, et al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteom. 2013;12:1589–601.
doi: 10.1074/mcp.M112.023887
Saraon P, Trudel D, Kron K, Dmitromanolakis A, Trachtenberg J, Bapat B, et al. Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. Prostate. 2014;74:372–80.
pubmed: 24311408 doi: 10.1002/pros.22758
Vezina CM, Lin TM, Peterson RE. AHR signaling in prostate growth, morphogenesis, and disease. Biochem. Pharmacol. 2009;77:566–76.
pubmed: 18977204 doi: 10.1016/j.bcp.2008.09.039
Gupta C. Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. Proc Soc Exp Biol Med. 2000;224:61–68.
pubmed: 10806412 doi: 10.1046/j.1525-1373.2000.22402.x
Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016;11:347–58.
pubmed: 26797458 pmcid: 4793718 doi: 10.1038/nprot.2016.006
Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, Van Boxtel R, Wongvipat J, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 2014;159:163–75.
pubmed: 25201529 pmcid: 4772677 doi: 10.1016/j.cell.2014.08.017
Lee HM, Hwang KA, Choi KC. Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process. Mol Cell Endocrinol. 2017;457:103–13.
pubmed: 28042023 doi: 10.1016/j.mce.2016.12.026
Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;3:209–21.
doi: 10.1016/S1535-6108(03)00215-0
Fletcher N, Wahlström D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol Appl Pharmacol. 2005;207:1–24.
pubmed: 16054898 doi: 10.1016/j.taap.2004.12.003
Cholico GN, Fling RR, Zacharewski NA, Fader KA, Nault R, Zacharewski TR. Thioesterase induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin results in a futile cycle that inhibits hepatic β-oxidation. Sci Rep. 2021;11:15689.
pubmed: 34344994 pmcid: 8333094 doi: 10.1038/s41598-021-95214-0
Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, et al. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021;40:6284–98.
pubmed: 34584218 pmcid: 8566229 doi: 10.1038/s41388-021-02008-9
Gearing LJ, Cumming HE, Chapman R, Finkel AM, Woodhouse IB, Luu K, et al. CiIIder: A tool for predicting and analysing transcription factor binding sites. PLoS ONE. 2019;14:e0215495.
pubmed: 31483836 pmcid: 6726224 doi: 10.1371/journal.pone.0215495
Li S, Pei X, Zhang W, Xie HQ, Zhao B. Functional analysis of the dioxin response elements (DREs) of the murine CYP1A1 gene promoter: beyond the core DRE sequence. Int J Mol Sci. 2014;15:6475–87.
pubmed: 24743890 pmcid: 4013641 doi: 10.3390/ijms15046475
Dere E, Lo R, Celius T, Matthews J, Zacharewski TR. Integration of genome-wide computation DRE search, AhR ChIP-chip and gene expression analyses of TCDD-elicited responses in the mouse liver. BMC Genomics. 2011;12:365.
pubmed: 21762485 pmcid: 3160422 doi: 10.1186/1471-2164-12-365
Poland A, Palen D, Glover E. Tumour promotion by TCDD in skin of HRS/J hairless mice. Nature. 1982;300:271–3.
pubmed: 7144882 doi: 10.1038/300271a0
Knerr S, Schrenk D. Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. Mol Nutr Food Res. 2006;50:897–907.
pubmed: 16977593 doi: 10.1002/mnfr.200600006
Wang L, Kumar M, Deng Q, Wang X, Liu M, Gong Z, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. Cancer Lett. 2019;440-441:135–44.
pubmed: 30343114 doi: 10.1016/j.canlet.2018.10.009
Prins GS, Hu WY, Shi GB, Hu DP, Majumdar S, Li G, et al. Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium. Endocrinology. 2014;155:805–17.
pubmed: 24424067 pmcid: 3929731 doi: 10.1210/en.2013-1955
Ghotbaddini M, Powell JB. The AhR ligand, TCDD, regulates androgen receptor activity differently in androgen-sensitive versus castration-resistant human prostate cancer cells. Int J Environ Res Public Health. 2015;12:7506–18.
pubmed: 26154658 pmcid: 4515671 doi: 10.3390/ijerph120707506
Peters AK, Leonards PE, Zhao B, Bergman Å, Denison MS, Van, et al. Determination of in vitro relative potency (REP) values for mono-ortho polychlorinated biphenyls after purification with active charcoal. Toxicol Lett. 2006;12:7506–18.
Kopec AK, Burgoon LD, Ibrahim-Aibo D, Mets BD, Tashiro C, Potter D, et al. PCB153-elicited hepatic responses in the immature, ovariectomized C57BL/6 mice: comparative toxicogenomic effects of dioxin and non-dioxin-like ligands. Toxicol Appl Pharmacol. 2010;243:359–71.
pubmed: 20005886 doi: 10.1016/j.taap.2009.12.003
Villano CM, Murphy KA, Akintobi A, White LA. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces matrix metalloproteinase (MMP) expression and invasion in A2058 melanoma cells. Toxicol Appl Pharmacol. 2006;210:212–24.
pubmed: 15982688 doi: 10.1016/j.taap.2005.05.001
Diry M, Tomkiewicz C, Koehle C, Coumoul X, Bock KW, Barouki R, et al. Activation of the dioxin/aryl hydrocarbon receptor (AhR) modulates cell plasticity through a JNK-dependent mechanism. Oncogene. 2006;25:5570–4.
pubmed: 16619036 doi: 10.1038/sj.onc.1209553
Seifert A, Rau S, Küllertz G, Fischer B, Santos AN. TCDD induces cell migration via NFATc1/ATX-signaling in MCF-7 cells. Toxicol Lett. 2009;184:26–32.
pubmed: 19028555 doi: 10.1016/j.toxlet.2008.10.026
Bui LC, Tomkiewicz C, Chevallier A, Pierre S, Bats AS, Mota S, et al. Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Oncogene. 2009;28:3642–51.
pubmed: 19648964 doi: 10.1038/onc.2009.224
Gao Z, Bu Y, Liu X, Wang X, Zhang G, Wang E, et al. TCDD promoted EMT of hFPECs via AhR, which involved the activation of EGFR/ERK signaling. Toxicol Appl Pharmacol. 2016;298:48–55.
pubmed: 26971374 doi: 10.1016/j.taap.2016.03.005
Haque M, Francis J, Sehgal I. Aryl hydrocarbon exposure induces expression of MMP-9 in human prostate cancer cell lines. Cancer Lett. 2005;225:159–66.
pubmed: 15922868 doi: 10.1016/j.canlet.2004.11.043
Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, et al. Metabolism disrupting chemicals and metabolic disorders. Reprod Toxicol. 2017;68:3–33.
pubmed: 27760374 doi: 10.1016/j.reprotox.2016.10.001
Shan Q, Li H, Chen N, Qu F, Guo J. Understanding the multiple effects of PCBS on lipid metabolism. Diabetes Metab Syndr Obes. 2020;13:3691–702.
pubmed: 33116719 pmcid: 7568599 doi: 10.2147/DMSO.S264851
Lakshman MR, Ghosh P, Chirtel SJ. Mechanism of action of 2,3,7,8-tetrachlorodibenzo-p-dioxin on intermediary metabolism in the rat. J Pharmacol Exp Ther. 1991;258:317–9.
pubmed: 2072303
Diani-Moore S, Pedro TM, Rifkind AB. Organ-specific effects on glycolysis by the dioxin-activated aryl hydrocarbon receptor. PLoS ONE. 2020;15:e0243842.
pubmed: 33320884 pmcid: 7737989 doi: 10.1371/journal.pone.0243842
Ambolet-Camoit A, Ottolenghi C, Leblanc A, Kim MJ, Letourneur F, Jacques S, et al. Two persistent organic pollutants which act through different xenosensors (alpha-endosulfan and 2,3,7,8 tetrachlorodibenzo-p-dioxin) interact in a mixture and downregulate multiple genes involved in human hepatocyte lipid and glucose metabolism. Biochimie. 2015;116:79–91.
pubmed: 26159488 doi: 10.1016/j.biochi.2015.07.003
Zhang Y, Song L, Li Z. Polychlorinated biphenyls promote cell survival through pyruvate kinase M2-dependent glycolysis in HeLa cells. Toxicol Mech Methods. 2019;29:428–37.
pubmed: 30821169 doi: 10.1080/15376516.2019.1584658
Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012;11:3964–71.
pubmed: 23082722 pmcid: 3507492 doi: 10.4161/cc.22137
Garcia-Bermudez J, Birsoy K. Drugging ACAT1 for cancer therapy. Mol Cell. 2016;64:856–7.
pubmed: 27912096 doi: 10.1016/j.molcel.2016.11.023
Mao T, Qin F, Zhang M, Li J, Li J, Lai M. Elevated serum β-hydroxybutyrate, a circulating ketone metabolite, accelerates colorectal cancer proliferation and metastasis via ACAT1. Oncogene. 2023;42:1889–99.
pubmed: 37185457 doi: 10.1038/s41388-023-02700-y
Zhang G, Huang R, Zhao H, Xia Y, Huang H, Qian M, et al. ACAT1-mediated METTL3 acetylation inhibits cell migration and invasion in triple negative breast cancer. Genes Immun. 2023;24:99–107.
pubmed: 36890220 doi: 10.1038/s41435-023-00202-1
Guan J, Jiang X, Guo Y, Zhao W, Li J, Li Y, et al. Autophagy inhibition and reactive oxygen species elimination by acetyl-CoA acetyltransferase 1 through fused in sarcoma protein to promote prostate cancer. BMC Cancer. 2022;22:1313.
pubmed: 36517760 pmcid: 9753422 doi: 10.1186/s12885-022-10426-5
Goudarzi A. The recent insights into the function of ACAT1: A possible anti-cancer therapeutic target. Life Sci. 2019;232:116592.
pubmed: 31228515 doi: 10.1016/j.lfs.2019.116592
Nault R, Fader KA, Lydic TA, Zacharewski TR. Lipidomic evaluation of aryl hydrocarbon receptor-mediated hepatic steatosis in male and female mice elicited by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Chem Res Toxicol. 2017;30:1060–75.
pubmed: 28238261 pmcid: 5896278 doi: 10.1021/acs.chemrestox.6b00430
Koual M, Cano-Sancho G, Bats AS, Tomkiewicz C, Kaddouch-Amar Y, Douay-Hauser N, et al. Associations between persistent organic pollutants and risk of breast cancer metastasis. Environ Int. 2019;132:105028.
pubmed: 31382183 doi: 10.1016/j.envint.2019.105028
Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.
pubmed: 17406473 doi: 10.1038/nprot.2006.339
Wu X, Wu J, Huang J, Powell WC, Zhang JF, Matusik RJ, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001;101:61–69.
pubmed: 11231059 doi: 10.1016/S0925-4773(00)00551-7
Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002;32:148–9.
pubmed: 11857804 doi: 10.1002/gene.10036
Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet. 2002;32:435–43.
pubmed: 12467341 pmcid: 1397713 doi: 10.1023/A:1020884312053
Van den Berg M, Birnbaum LS, Denison M, De Vito M, Farland W, Feeley M, et al. The 2005 World Health Organization reevaluation of human and mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol Sci. 2006;93:223–41.
pubmed: 16829543 doi: 10.1093/toxsci/kfl055
Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol. 2003;31:31–38.
pubmed: 12597447 doi: 10.1080/01926230390173842
Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, et al. An in vivo mouse model for human prostate cancer metastasis. Neoplasia. 2008;10:371–80.
pubmed: 18392141 pmcid: 2288546 doi: 10.1593/neo.08154
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
pubmed: 11846609 doi: 10.1006/meth.2001.1262
Lee E, Choi J, Jo Y, Kim JY, Jang YJ, Lee HM, et al. ACT-PRESTO: Rapid and consistent tissue clearing and labeling method for 3-dimensional (3D) imaging. Sci Rep. 2016;11:18631.
doi: 10.1038/srep18631

Auteurs

Julio Buñay (J)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Myriam Kossai (M)

Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000, Clermont Ferrand, France.

Christelle Damon-Soubeyrant (C)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Angélique De Haze (A)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Jean-Paul Saru (JP)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Amalia Trousson (A)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Cyrille de Joussineau (C)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Erwan Bouchareb (E)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Ayhan Kocer (A)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Marine Vialat (M)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Sarah Dallel (S)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.
Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU Clermont Ferrand, Hôpital Gabriel Montpied, F-63003, Clermont-Ferrand, France.

Françoise Degoul (F)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Frédéric Bost (F)

Université Côte d'Azur, INSERM U1065, C3M, Equipe Labellisée Ligue Nationale contre le Cancer, 2022, F-06204, Nice, France.

Stephan Clavel (S)

Université Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS UMR7275, Sophia-Antipolis, Valbonne, France.

Frédérique Penault-Llorca (F)

Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000, Clermont Ferrand, France.

Marie-Pierre Valli (MP)

Service d'Urologie, CHU Clermont-Ferrand, UMR1240 INSERM, Université Clermont-Auvergne, Clermont Ferrand, France.

Laurent Guy (L)

Service d'Urologie, CHU Clermont-Ferrand, UMR1240 INSERM, Université Clermont-Auvergne, Clermont Ferrand, France.

Jason Matthews (J)

Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Yoan Renaud (Y)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Michael Ittmann (M)

Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Center for Metabolism and Experimental Therapeutics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, and Michael E. DeBakey VAMC Houston, Houston, TX, 77030, USA.

Jeffrey Jones (J)

Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Department of Urology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Operative Care Line, Urology Section, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, 77030, USA.

Laurent Morel (L)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Jean-Marc Lobaccaro (JM)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France.

Silvère Baron (S)

Université Clermont Auvergne, iGReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France. silvere.baron@uca.fr.
Groupe Cancer Clermont Auvergne, 28, place Henri Dunant, BP38, 63001, Clermont-Ferrand, France. silvere.baron@uca.fr.
Centre de Recherche en Nutrition Humaine d'Auvergne, 58 Boulevard Montalembert, F-63009, Clermont-Ferrand, France. silvere.baron@uca.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH